{"ticker": {"uuid": "9d2a273c-12de-4c23-a429-8197d59dab59", "symbol": "KROS", "name": "Keros Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Keros Therapeutics Inc (KROS), noting its current valuation score is 7.27, ranking 244 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.21, and mentions that relevant data for P/", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T02:09:20", "published_display": "19 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(KROS) Movement Within Algorithmic Entry Frameworks", "summary": "Keros Therapeutics Inc. (NASDAQ: KROS) is showing a mid-channel oscillation pattern with strong near-term sentiment that could challenge persistent mid and long-term weakness. Algorithmic analysis highlights an exceptional 112.7:1 risk-reward setup targeting a 35.7% gain against ", "url": "https://news.stocktradersdaily.com/news_release/139/KROS_Movement_Within_Algorithmic_Entry_Frameworks_061826115801_1781841481.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T00:09:20", "published_display": "19 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS", "summary": "Madison Avenue Partners LP significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 69.6% in the fourth quarter of 2025. This institutional activity occurred alongside insider selling and a weaker-than-expected quarterly earnings report from Keros Therapeutics. Desp", "url": "https://www.marketbeat.com/instant-alerts/filing-madison-avenue-partners-lp-reduces-stock-holdings-in-keros-therapeutics-inc-kros-2026-06-18/", "source_name": "MarketBeat", "published_at": "2026-06-18T11:40:12", "published_display": "18 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Institutional Confidence", "summary": "This article analyzes the institutional confidence in Keros Therapeutics Inc (KROS), noting its current institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:12", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Keros Therapeutics Inc (KROS), highlighting its current price momentum score of 6.27 within the Biotechnology & Medical Research industry. It details the stock's trading range between resistance at $11.46 and support at $9.52, and pre", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:33", "published_display": "18 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Keros Therapeutics Inc (KROS), covering business segments, regional revenue, and profit contribution. It notes that relevant data for these categories have not yet been disclosed by the company. The current stock price of KROS is pro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:33", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan", "summary": "Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock at a weighted average price of $10.19 per share. This open-market transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, meaning it was pre-scheduled. Followin", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-fa200c65d5e3.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:33", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Charles W. Newton sells $5,521 in shares", "summary": "Keros Therapeutics director Charles W. Newton sold 550 shares of the company's common stock for a total of $5,521 on June 11, 2026. The sale was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week low. Despite the recent price decli", "url": "https://www.investing.com/news/insider-trading-news/keros-therapeutics-director-charles-w-newton-sells-5521-in-shares-93CH-4743104", "source_name": "Investing.com", "published_at": "2026-06-16T00:39:52", "published_display": "16 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com", "summary": "Charles W. Newton, a director at Keros Therapeutics, Inc. (NASDAQ:KROS), sold 550 shares of the company\u2019s common stock for a total of $5,521. The sale occurred on June 11, 2026, with shares trading between $9.83 and $10.16. Despite the stock being near its 52-week low and down 52", "url": "https://ng.investing.com/news/insider-trading-news/keros-therapeutics-director-charles-w-newton-sells-5521-in-shares-93CH-2559049", "source_name": "Investing.com Nigeria", "published_at": "2026-06-15T21:09:57", "published_display": "15 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade", "summary": "Keros Therapeutics director Charles W. Newton sold 550 shares of common stock at a weighted average price of $10.04 per share, a transaction conducted on June 11, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Newton directly holds 12,665 shares of Kero", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-878bc9ce6b77.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:39:52", "published_display": "15 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $20.2, Implies 99% Upside", "summary": "Keros Therapeutics, Inc.'s average price target has been reduced from $21.83 to $20.2 by 5 analysts, with forecasts ranging from $16 to $25 per share. This new target implies a potential upside of approximately 99% based on the June 12 closing price. The consensus rating for the ", "url": "https://www.tradingview.com/news/tradingview:1cfbcc2b05d70:0-keros-therapeutics-inc-stock-12-month-price-target-cut-to-20-2-implies-99-upside/", "source_name": "TradingView", "published_at": "2026-06-13T05:20:22", "published_display": "13 Jun 2026 05:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Keros Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Keros Therapeutics, Inc. (KROS). The filing details the proposed sale of 550 shares of common stock by an individual, acquired through an RSU on May 15, 2026, with an aggregate market value of $5,472.50. The shares are expected to ", "url": "https://www.stocktitan.net/sec-filings/KROS/144-keros-therapeutics-inc-sec-filing-4e282633e4a1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:16", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Nima sells $28,166 in company stock", "summary": "Nima Farzan, a director at Keros Therapeutics, sold 2,625 shares of company stock worth $28,166 on June 4, 2026, under a pre-arranged trading plan. This transaction occurred while the stock was trading near its 52-week low and had declined significantly over the past six months. ", "url": "https://www.investing.com/news/insider-trading-news/keros-therapeutics-director-nima-sells-28166-in-company-stock-93CH-4731594", "source_name": "Investing.com", "published_at": "2026-06-09T06:09:16", "published_display": "09 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObXR4TWRUaElFdk10QTN5QkdhUWNIUEJQTU93V3I3QVdGZ2ZXdF9Jem1KRTFjYnZqY2xFZHpNVm11RldyRTJZTGZxVm1ZWXJNdEx1c2swb1FOMDNaTC1WT2J6TDIzMXZTVWVZeURQcnI3bVUwSzJCSXdJUHRiQVFfVW9HaEZYNGRMa1JxRUlOQVpHRExOTjVzbUp4bUNUdFBLTGN1N0JOWVI2UkNvbFllYmRkTlN6b3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdnFCaVV3Z3NHajc5b1pRVk1DMlJmYTc4TUk3Zzc1d1U3NmlGYTRIRjk1cUY3MTJ1UGlXRXlvaVBaQWlXeUNnR0dtZllfODBqekQwbERSMlJHTXkzRUdRZzkxNHFIUXFvdGM2TW5OWmRScmNzVlN4Y0JOTlhReWxSTVhPWS1QakZ2eFRrVXZneE9idVE4TFJ5dXZxc3NYeW9ISjdibWRKU0IxSlVIdElFOFNTSFhoYnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS)", "summary": "Alpna Seth, a Director at Keros Therapeutics Inc (KROS), sold 2,625 shares of the company on June 4, 2026. This transaction leaves her with 9,767 shares. Keros Therapeutics is a clinical-stage biopharmaceutical company, and its stock was trading at $10.72 per share on the day of ", "url": "https://www.gurufocus.com/news/8903805/insider-sell-alpna-seth-sells-shares-of-keros-therapeutics-inc-kros", "source_name": "GuruFocus", "published_at": "2026-06-05T22:38:55", "published_display": "05 Jun 2026 22:38", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director granted RSUs and options | KROS Insider Trading", "summary": "Keros Therapeutics director Alpna Seth was granted 7,142 restricted stock units (RSUs) and a stock option for 7,433 shares with an exercise price of $10.50, as reported in a recent Form 4 filing. This compensation-related grant means she did not purchase shares on the open market", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-6ae66d8b5fd4.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:38:55", "published_display": "05 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant", "summary": "Keros Therapeutics director Jean Jacques Bienaime received 7,142 restricted stock units (RSUs) and options for 7,433 shares of Common Stock with an exercise price of $10.50 per share. These equity awards are compensation-related and not open-market trades. Following the grant, Bi", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-5907511cb828.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:56", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards", "summary": "Keros Therapeutics director Mary Ann Gray was granted 7,142 restricted stock units (RSUs) and options for 7,433 shares at an exercise price of $10.50. The RSUs vest by June 3, 2027, or the 2027 annual meeting, while the stock options vest quarterly over 12 months after June 3, 20", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-51e6a4f7dab8.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:55", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan", "summary": "Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 common shares at a weighted average price of $10.72 per share on June 4, 2026. The sale, made between $10.60 and $10.89, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 9,", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-7425f863a094.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:55", "published_display": "05 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. SEC Filing", "summary": "This article reports on Keros Therapeutics, Inc.'s SEC Form 144 filing, indicating a proposed sale of securities. The document details the filer and issuer information, the nature of the securities to be sold (Common Stock), and their acquisition details, noting a neutral impact ", "url": "https://www.stocktitan.net/sec-filings/KROS/144-keros-therapeutics-inc-sec-filing-1a506505af52.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:01", "published_display": "04 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay", "summary": "Keros Therapeutics (NASDAQ: KROS) stockholders approved all proposals at their 2026 Annual Meeting. Key decisions included the election of Jean-Jacques Bienaim\u00e9 and Charles Newton as directors, the ratification of Deloitte & Touche LLP as the company's independent auditor for 202", "url": "https://www.stocktitan.net/sec-filings/KROS/8-k-keros-therapeutics-inc-reports-material-event-6c20bb0f9675.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:39:31", "published_display": "03 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $21.83, Implies 107% Upside", "summary": "Keros Therapeutics, Inc. (KROS) has seen its average 12-month price target adjusted downwards to $21.83 from $22.2, according to estimates from six analysts. Despite the cut, this new target still suggests approximately 107% potential upside based on the June 2nd closing price. T", "url": "https://www.tradingview.com/news/tradingview:2533927ea2270:0-keros-therapeutics-inc-stock-12-month-price-target-cut-to-21-83-implies-107-upside/", "source_name": "TradingView", "published_at": "2026-06-03T17:39:30", "published_display": "03 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "Keros Therapeutics, Inc. announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304698/0/en/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T15:39:43", "published_display": "02 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat", "summary": "Keros Therapeutics announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. The company is a clinical-stage biopharmaceutical firm focusing on therapeutics ", "url": "https://www.stocktitan.net/sec-filings/KROS/8-k-keros-therapeutics-inc-reports-material-event-3f56c8ea7e9c.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:24", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics CEO to speak at Goldman Sachs health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYmJvZmNPVnFSczVybHhUMnNQWUk0LUdkMUMxM3NEcHI2a2t2dmhhOFBRM1hrM2laSTUtNlhacDA4amdURUVIT0VGTTJmWnFTYlJIV2VIV3F4VVMxSlQ2LUpuYmxqamVmSEVNbkhWci0tUFlQOEpVTU1NSVFLLVdsVDNjX1RjVkpfS1BScHN0LWtKanlxRHBrVU5oZk5nMnVmaEJkbHMyaTVzVTJFOXZ1Y3RjZXdBLVFQUjRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (KROS) Volatility", "summary": "Keros Therapeutics Inc. (NASDAQ: KROS) is experiencing volatility with strong near-term sentiment potentially challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with a m", "url": "https://news.stocktradersdaily.com/news_release/151/Trading_Systems_Reacting_to_KROS_Volatility_052726092002_1779931202.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-27T21:20:00", "published_display": "27 May 2026 21:20", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KROS Stock Guide to Rinvatercept in DMD and ALS for 2026", "summary": "Keros Therapeutics (KROS) is focusing on its lead neuromuscular program, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) in 2026. The drug aims to modulate transforming growth factor-beta family signaling to promote muscle gro", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/2088561/kros-stock-guide-to-rinvatercept-in-dmd-and-als-for-2026/", "source_name": "The Globe and Mail", "published_at": "2026-05-22T16:09:19", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates", "summary": "Keros Therapeutics, Inc. (KROS) reported a Q1 loss, missing revenue estimates. The company's financial performance highlights challenges in meeting market expectations for the quarter.", "url": "https://www.msn.com/en-us/money/other/keros-therapeutics-inc-kros-reports-q1-loss-misses-revenue-estimates/ar-AA23bsYj?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T21:09:19", "published_display": "21 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles", "summary": "Keros Therapeutics (KROS:NASDAQ) announced that the initiation of its Phase 2 rinvatercept study for Duchenne muscular dystrophy (DMD) will be delayed from Q2 2026 to Q3 2026 due to procedural regulatory hurdles. Wedbush Securities analyst Yun Zhong reiterated a Neutral rating wi", "url": "https://www.streetwisereports.com/article/2026/05/20/lexington-ma-biotech-pushes-dmd-phase-2-start-to-3q26-on-regulatory-hurdles.html", "source_name": "Streetwise Reports", "published_at": "2026-05-20T16:09:50", "published_display": "20 May 2026 16:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16", "summary": "Wedbush has reiterated its Hold rating on Keros Therapeutics (KROS.US) and maintained its target price at $16. This report indicates a continued neutral stance on the company's stock by the analyst firm.", "url": "https://www.moomoo.com/news/post/70265593/wedbush-maintains-keros-therapeutics-krosus-with-hold-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-05-20T06:09:50", "published_display": "20 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan", "summary": "A director at Keros Therapeutics, Jean Jacques Bienaime, purchased 1,000 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $10.58 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on D", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-84c3a845b20b.html", "source_name": "Stock Titan", "published_at": "2026-05-19T20:09:26", "published_display": "19 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQTFVoZUxBd1dCOXV5TDgxQUhodXFwN0pVWHNLUW9EUjQ3ZDhpekRHUEl1djk2YVl5Q3dlS2hxVjI5dTh6M1dOQnRvUldzVE9xeE14WG0xaFBUNGlQaDFKRU1oSDVFRHI5bnRmal9Xem5HVlRqVERERFZfNWRSbDRsNXRXZjRLWi1LYlV2Y1RSZGlTSEhFUGJXdlgtNzd5Rzl6S0E?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdnplVkI0aGFNWlhTQmFsZ1FxNFFpVWRyc0JmbDMwY2ZvTmo5WGpRQ3VWaW5fdEZOZTVseE1sQmUwMnQxWnpaTjdGcW9HSFE3R3lfcXVYczJDWnozMHR6VVR5Nk1nb1Y2cGlOUXN3aGZ2a2pvcXNCZEQyVHhkcWtIdTFvWUs0dE5PWUQ3TVk1cEVlMWQtaEpRU0dPSE1HUGJLcWpNTGZhVW5lUWpxcjNiSUNKMW9ubWZ5?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZThpUUhfMVpqOTRuSmoxWVY2MUJmQjJtZXB4T2swMkF2bjJCa1lPTm5CSldQRXdZazRpQWNiTXpMdFAzTklKVGRVN3B6UDJ4YjBGQXpKQTA5azBleHVIRUp6SzVET25qdGVKN1lINXRWaGZyRDJPOTJSYndLMlBEVnptQ3Fqa2Ex?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTU5lVWdDQmlYamFXSzBsSnNHQzFfOEpLNGN4cmxPMEozVUktNjEyRkFPNW1hMzhORDBqeGxUc0VYakR0d1ZZTElLMHQydkZuWC02VmRwNXVqN0xuRnhOdWJUazhyOUxjeXBuZ3NnNXJfQ0RNU3RaNUFWLWhvS2c5b0RHQkN4ZnBkQXd1Z0M1aEVETUdZY1Fvb1JINXpsLWhpRUJ6MXBGR1M1Wi1oSnoxbHhnbHZ1a3ozaGFHbzR5dzg?oc=5", "source_name": "TradingView", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Keros Therapeutics Stock Built to Withstand More Downside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNZld4UHgwR0lVamhNeHJoa05YMlhrem85bWQ2M09FNXdaTzFKT3Z2MXRHYmNrZnZmLThqT2RPSTUzRy1SbmNtTlUtODFIUVRhWnZVSEU0dGNTWlhfSVVRaDk2NFRVcVFNYXNSM0JKZ3UzY25rdVRKZ0FWc1VWbEd3SU9UVlRZNTk3TjZqTVRZYkJSUXlydGxCbWNtN1h5MG1kVWhVbEpRMC10X2hSbmk2dW9pSmV6WFNYd1hCQk1Yd2ttdHo1d2E4Wm8yNA?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQUC01Y3RQRU1iWXFWa283dzNUdE0yOU1hR0hPbnFHMjZDWXJQZ1NxNlJLS2hENEpwNFF4TVRLMThxYzRCX2lfbzRLYTRPUnJEb19oVzQ0end4VDhKYXFENUlWODFwU2NwcW03UUNMa0xoVkd6eGo3NFkydnp1RFJpemhEenBpOFQtWkNsaUVWVk9TR0pLVzhyd2RWY2s0OTdYY2lNem9GeXVyU0VGcGMzeWRCN0JDaHlnUDc4TVhqOURiV2xBMXlaRGZWcVF0SGhxX0d3ZkthdUJ5SW81MWxHc0FR?oc=5", "source_name": "Reuters", "published_at": "2024-12-12T08:00:00+00:00", "published_display": "12 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) Stock Price, News & Analysis $KROS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1WRWR4d3VkelhxQzFMMk42TXo3MEFwbWRfanJxeFNkNTJza2lOVXAxUkt0d1JRaVBPcENOWkxESFRzTmZmaTQtZWV1YWpKR0VqRzc5VHBLRk9iQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-15T02:18:29+00:00", "published_display": "15 Apr 2020 02:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Keros Therapeutics Inc (KROS), noting its current valuation score is 7.27, ranking 244 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.21, and mentions that relevant data for P/", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T02:09:20", "published_display": "19 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(KROS) Movement Within Algorithmic Entry Frameworks", "summary": "Keros Therapeutics Inc. (NASDAQ: KROS) is showing a mid-channel oscillation pattern with strong near-term sentiment that could challenge persistent mid and long-term weakness. Algorithmic analysis highlights an exceptional 112.7:1 risk-reward setup targeting a 35.7% gain against ", "url": "https://news.stocktradersdaily.com/news_release/139/KROS_Movement_Within_Algorithmic_Entry_Frameworks_061826115801_1781841481.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T00:09:20", "published_display": "19 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS", "summary": "Madison Avenue Partners LP significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 69.6% in the fourth quarter of 2025. This institutional activity occurred alongside insider selling and a weaker-than-expected quarterly earnings report from Keros Therapeutics. Desp", "url": "https://www.marketbeat.com/instant-alerts/filing-madison-avenue-partners-lp-reduces-stock-holdings-in-keros-therapeutics-inc-kros-2026-06-18/", "source_name": "MarketBeat", "published_at": "2026-06-18T11:40:12", "published_display": "18 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Institutional Confidence", "summary": "This article analyzes the institutional confidence in Keros Therapeutics Inc (KROS), noting its current institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:12", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Keros Therapeutics Inc (KROS), highlighting its current price momentum score of 6.27 within the Biotechnology & Medical Research industry. It details the stock's trading range between resistance at $11.46 and support at $9.52, and pre", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:33", "published_display": "18 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Keros Therapeutics Inc (KROS), covering business segments, regional revenue, and profit contribution. It notes that relevant data for these categories have not yet been disclosed by the company. The current stock price of KROS is pro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kros/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:33", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan", "summary": "Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock at a weighted average price of $10.19 per share. This open-market transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, meaning it was pre-scheduled. Followin", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-fa200c65d5e3.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:33", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Charles W. Newton sells $5,521 in shares", "summary": "Keros Therapeutics director Charles W. Newton sold 550 shares of the company's common stock for a total of $5,521 on June 11, 2026. The sale was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week low. Despite the recent price decli", "url": "https://www.investing.com/news/insider-trading-news/keros-therapeutics-director-charles-w-newton-sells-5521-in-shares-93CH-4743104", "source_name": "Investing.com", "published_at": "2026-06-16T00:39:52", "published_display": "16 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com", "summary": "Charles W. Newton, a director at Keros Therapeutics, Inc. (NASDAQ:KROS), sold 550 shares of the company\u2019s common stock for a total of $5,521. The sale occurred on June 11, 2026, with shares trading between $9.83 and $10.16. Despite the stock being near its 52-week low and down 52", "url": "https://ng.investing.com/news/insider-trading-news/keros-therapeutics-director-charles-w-newton-sells-5521-in-shares-93CH-2559049", "source_name": "Investing.com Nigeria", "published_at": "2026-06-15T21:09:57", "published_display": "15 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade", "summary": "Keros Therapeutics director Charles W. Newton sold 550 shares of common stock at a weighted average price of $10.04 per share, a transaction conducted on June 11, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Newton directly holds 12,665 shares of Kero", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-878bc9ce6b77.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:39:52", "published_display": "15 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $20.2, Implies 99% Upside", "summary": "Keros Therapeutics, Inc.'s average price target has been reduced from $21.83 to $20.2 by 5 analysts, with forecasts ranging from $16 to $25 per share. This new target implies a potential upside of approximately 99% based on the June 12 closing price. The consensus rating for the ", "url": "https://www.tradingview.com/news/tradingview:1cfbcc2b05d70:0-keros-therapeutics-inc-stock-12-month-price-target-cut-to-20-2-implies-99-upside/", "source_name": "TradingView", "published_at": "2026-06-13T05:20:22", "published_display": "13 Jun 2026 05:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Keros Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Keros Therapeutics, Inc. (KROS). The filing details the proposed sale of 550 shares of common stock by an individual, acquired through an RSU on May 15, 2026, with an aggregate market value of $5,472.50. The shares are expected to ", "url": "https://www.stocktitan.net/sec-filings/KROS/144-keros-therapeutics-inc-sec-filing-4e282633e4a1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:16", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director Nima sells $28,166 in company stock", "summary": "Nima Farzan, a director at Keros Therapeutics, sold 2,625 shares of company stock worth $28,166 on June 4, 2026, under a pre-arranged trading plan. This transaction occurred while the stock was trading near its 52-week low and had declined significantly over the past six months. ", "url": "https://www.investing.com/news/insider-trading-news/keros-therapeutics-director-nima-sells-28166-in-company-stock-93CH-4731594", "source_name": "Investing.com", "published_at": "2026-06-09T06:09:16", "published_display": "09 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObXR4TWRUaElFdk10QTN5QkdhUWNIUEJQTU93V3I3QVdGZ2ZXdF9Jem1KRTFjYnZqY2xFZHpNVm11RldyRTJZTGZxVm1ZWXJNdEx1c2swb1FOMDNaTC1WT2J6TDIzMXZTVWVZeURQcnI3bVUwSzJCSXdJUHRiQVFfVW9HaEZYNGRMa1JxRUlOQVpHRExOTjVzbUp4bUNUdFBLTGN1N0JOWVI2UkNvbFllYmRkTlN6b3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdnFCaVV3Z3NHajc5b1pRVk1DMlJmYTc4TUk3Zzc1d1U3NmlGYTRIRjk1cUY3MTJ1UGlXRXlvaVBaQWlXeUNnR0dtZllfODBqekQwbERSMlJHTXkzRUdRZzkxNHFIUXFvdGM2TW5OWmRScmNzVlN4Y0JOTlhReWxSTVhPWS1QakZ2eFRrVXZneE9idVE4TFJ5dXZxc3NYeW9ISjdibWRKU0IxSlVIdElFOFNTSFhoYnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS)", "summary": "Alpna Seth, a Director at Keros Therapeutics Inc (KROS), sold 2,625 shares of the company on June 4, 2026. This transaction leaves her with 9,767 shares. Keros Therapeutics is a clinical-stage biopharmaceutical company, and its stock was trading at $10.72 per share on the day of ", "url": "https://www.gurufocus.com/news/8903805/insider-sell-alpna-seth-sells-shares-of-keros-therapeutics-inc-kros", "source_name": "GuruFocus", "published_at": "2026-06-05T22:38:55", "published_display": "05 Jun 2026 22:38", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics director granted RSUs and options | KROS Insider Trading", "summary": "Keros Therapeutics director Alpna Seth was granted 7,142 restricted stock units (RSUs) and a stock option for 7,433 shares with an exercise price of $10.50, as reported in a recent Form 4 filing. This compensation-related grant means she did not purchase shares on the open market", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-6ae66d8b5fd4.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:38:55", "published_display": "05 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant", "summary": "Keros Therapeutics director Jean Jacques Bienaime received 7,142 restricted stock units (RSUs) and options for 7,433 shares of Common Stock with an exercise price of $10.50 per share. These equity awards are compensation-related and not open-market trades. Following the grant, Bi", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-5907511cb828.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:56", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards", "summary": "Keros Therapeutics director Mary Ann Gray was granted 7,142 restricted stock units (RSUs) and options for 7,433 shares at an exercise price of $10.50. The RSUs vest by June 3, 2027, or the 2027 annual meeting, while the stock options vest quarterly over 12 months after June 3, 20", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-51e6a4f7dab8.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:55", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan", "summary": "Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 common shares at a weighted average price of $10.72 per share on June 4, 2026. The sale, made between $10.60 and $10.89, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 9,", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-7425f863a094.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:55", "published_display": "05 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. SEC Filing", "summary": "This article reports on Keros Therapeutics, Inc.'s SEC Form 144 filing, indicating a proposed sale of securities. The document details the filer and issuer information, the nature of the securities to be sold (Common Stock), and their acquisition details, noting a neutral impact ", "url": "https://www.stocktitan.net/sec-filings/KROS/144-keros-therapeutics-inc-sec-filing-1a506505af52.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:01", "published_display": "04 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay", "summary": "Keros Therapeutics (NASDAQ: KROS) stockholders approved all proposals at their 2026 Annual Meeting. Key decisions included the election of Jean-Jacques Bienaim\u00e9 and Charles Newton as directors, the ratification of Deloitte & Touche LLP as the company's independent auditor for 202", "url": "https://www.stocktitan.net/sec-filings/KROS/8-k-keros-therapeutics-inc-reports-material-event-6c20bb0f9675.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:39:31", "published_display": "03 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $21.83, Implies 107% Upside", "summary": "Keros Therapeutics, Inc. (KROS) has seen its average 12-month price target adjusted downwards to $21.83 from $22.2, according to estimates from six analysts. Despite the cut, this new target still suggests approximately 107% potential upside based on the June 2nd closing price. T", "url": "https://www.tradingview.com/news/tradingview:2533927ea2270:0-keros-therapeutics-inc-stock-12-month-price-target-cut-to-21-83-implies-107-upside/", "source_name": "TradingView", "published_at": "2026-06-03T17:39:30", "published_display": "03 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "Keros Therapeutics, Inc. announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304698/0/en/keros-therapeutics-announces-participation-at-goldman-sachs-47th-annual-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T15:39:43", "published_display": "02 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat", "summary": "Keros Therapeutics announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. The company is a clinical-stage biopharmaceutical firm focusing on therapeutics ", "url": "https://www.stocktitan.net/sec-filings/KROS/8-k-keros-therapeutics-inc-reports-material-event-3f56c8ea7e9c.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:24", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics CEO to speak at Goldman Sachs health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYmJvZmNPVnFSczVybHhUMnNQWUk0LUdkMUMxM3NEcHI2a2t2dmhhOFBRM1hrM2laSTUtNlhacDA4amdURUVIT0VGTTJmWnFTYlJIV2VIV3F4VVMxSlQ2LUpuYmxqamVmSEVNbkhWci0tUFlQOEpVTU1NSVFLLVdsVDNjX1RjVkpfS1BScHN0LWtKanlxRHBrVU5oZk5nMnVmaEJkbHMyaTVzVTJFOXZ1Y3RjZXdBLVFQUjRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (KROS) Volatility", "summary": "Keros Therapeutics Inc. (NASDAQ: KROS) is experiencing volatility with strong near-term sentiment potentially challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with a m", "url": "https://news.stocktradersdaily.com/news_release/151/Trading_Systems_Reacting_to_KROS_Volatility_052726092002_1779931202.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-27T21:20:00", "published_display": "27 May 2026 21:20", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KROS Stock Guide to Rinvatercept in DMD and ALS for 2026", "summary": "Keros Therapeutics (KROS) is focusing on its lead neuromuscular program, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) in 2026. The drug aims to modulate transforming growth factor-beta family signaling to promote muscle gro", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/2088561/kros-stock-guide-to-rinvatercept-in-dmd-and-als-for-2026/", "source_name": "The Globe and Mail", "published_at": "2026-05-22T16:09:19", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates", "summary": "Keros Therapeutics, Inc. (KROS) reported a Q1 loss, missing revenue estimates. The company's financial performance highlights challenges in meeting market expectations for the quarter.", "url": "https://www.msn.com/en-us/money/other/keros-therapeutics-inc-kros-reports-q1-loss-misses-revenue-estimates/ar-AA23bsYj?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T21:09:19", "published_display": "21 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles", "summary": "Keros Therapeutics (KROS:NASDAQ) announced that the initiation of its Phase 2 rinvatercept study for Duchenne muscular dystrophy (DMD) will be delayed from Q2 2026 to Q3 2026 due to procedural regulatory hurdles. Wedbush Securities analyst Yun Zhong reiterated a Neutral rating wi", "url": "https://www.streetwisereports.com/article/2026/05/20/lexington-ma-biotech-pushes-dmd-phase-2-start-to-3q26-on-regulatory-hurdles.html", "source_name": "Streetwise Reports", "published_at": "2026-05-20T16:09:50", "published_display": "20 May 2026 16:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16", "summary": "Wedbush has reiterated its Hold rating on Keros Therapeutics (KROS.US) and maintained its target price at $16. This report indicates a continued neutral stance on the company's stock by the analyst firm.", "url": "https://www.moomoo.com/news/post/70265593/wedbush-maintains-keros-therapeutics-krosus-with-hold-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-05-20T06:09:50", "published_display": "20 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan", "summary": "A director at Keros Therapeutics, Jean Jacques Bienaime, purchased 1,000 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $10.58 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on D", "url": "https://www.stocktitan.net/sec-filings/KROS/form-4-keros-therapeutics-inc-insider-trading-activity-84c3a845b20b.html", "source_name": "Stock Titan", "published_at": "2026-05-19T20:09:26", "published_display": "19 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQTFVoZUxBd1dCOXV5TDgxQUhodXFwN0pVWHNLUW9EUjQ3ZDhpekRHUEl1djk2YVl5Q3dlS2hxVjI5dTh6M1dOQnRvUldzVE9xeE14WG0xaFBUNGlQaDFKRU1oSDVFRHI5bnRmal9Xem5HVlRqVERERFZfNWRSbDRsNXRXZjRLWi1LYlV2Y1RSZGlTSEhFUGJXdlgtNzd5Rzl6S0E?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdnplVkI0aGFNWlhTQmFsZ1FxNFFpVWRyc0JmbDMwY2ZvTmo5WGpRQ3VWaW5fdEZOZTVseE1sQmUwMnQxWnpaTjdGcW9HSFE3R3lfcXVYczJDWnozMHR6VVR5Nk1nb1Y2cGlOUXN3aGZ2a2pvcXNCZEQyVHhkcWtIdTFvWUs0dE5PWUQ3TVk1cEVlMWQtaEpRU0dPSE1HUGJLcWpNTGZhVW5lUWpxcjNiSUNKMW9ubWZ5?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZThpUUhfMVpqOTRuSmoxWVY2MUJmQjJtZXB4T2swMkF2bjJCa1lPTm5CSldQRXdZazRpQWNiTXpMdFAzTklKVGRVN3B6UDJ4YjBGQXpKQTA5azBleHVIRUp6SzVET25qdGVKN1lINXRWaGZyRDJPOTJSYndLMlBEVnptQ3Fqa2Ex?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTU5lVWdDQmlYamFXSzBsSnNHQzFfOEpLNGN4cmxPMEozVUktNjEyRkFPNW1hMzhORDBqeGxUc0VYakR0d1ZZTElLMHQydkZuWC02VmRwNXVqN0xuRnhOdWJUazhyOUxjeXBuZ3NnNXJfQ0RNU3RaNUFWLWhvS2c5b0RHQkN4ZnBkQXd1Z0M1aEVETUdZY1Fvb1JINXpsLWhpRUJ6MXBGR1M1Wi1oSnoxbHhnbHZ1a3ozaGFHbzR5dzg?oc=5", "source_name": "TradingView", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Keros Therapeutics Stock Built to Withstand More Downside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNZld4UHgwR0lVamhNeHJoa05YMlhrem85bWQ2M09FNXdaTzFKT3Z2MXRHYmNrZnZmLThqT2RPSTUzRy1SbmNtTlUtODFIUVRhWnZVSEU0dGNTWlhfSVVRaDk2NFRVcVFNYXNSM0JKZ3UzY25rdVRKZ0FWc1VWbEd3SU9UVlRZNTk3TjZqTVRZYkJSUXlydGxCbWNtN1h5MG1kVWhVbEpRMC10X2hSbmk2dW9pSmV6WFNYd1hCQk1Yd2ttdHo1d2E4Wm8yNA?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQUC01Y3RQRU1iWXFWa283dzNUdE0yOU1hR0hPbnFHMjZDWXJQZ1NxNlJLS2hENEpwNFF4TVRLMThxYzRCX2lfbzRLYTRPUnJEb19oVzQ0end4VDhKYXFENUlWODFwU2NwcW03UUNMa0xoVkd6eGo3NFkydnp1RFJpemhEenBpOFQtWkNsaUVWVk9TR0pLVzhyd2RWY2s0OTdYY2lNem9GeXVyU0VGcGMzeWRCN0JDaHlnUDc4TVhqOURiV2xBMXlaRGZWcVF0SGhxX0d3ZkthdUJ5SW81MWxHc0FR?oc=5", "source_name": "Reuters", "published_at": "2024-12-12T08:00:00+00:00", "published_display": "12 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Keros Therapeutics (KROS) Stock Price, News & Analysis $KROS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1WRWR4d3VkelhxQzFMMk42TXo3MEFwbWRfanJxeFNkNTJza2lOVXAxUkt0d1JRaVBPcENOWkxESFRzTmZmaTQtZWV1YWpKR0VqRzc5VHBLRk9iQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-15T02:18:29+00:00", "published_display": "15 Apr 2020 02:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 48, "sentiment_summary": {"positive": 11, "negative": 14, "neutral": 23, "score": 49, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.74, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 14}, "market_context": {"has_market_context": true, "latest_close": 10.65, "latest_week": "2026-06-19", "one_week_move": 4.9, "four_week_move": -4.8, "twelve_week_move": 0.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.145984, "market_dynamics_buy_signal": false, "relative_strength": -40.90894, "fair_value_gap": -65.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.1235, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.9% over one week, -4.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.9% over one week, -4.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis"}], "updated_at": "2026-06-22T15:05:42.931112+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}